Annual Report 2003 Aventis - Sanofi
Annual Report 2003 Aventis - Sanofi
Annual Report 2003 Aventis - Sanofi
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
still constitute a signifi cant part of our business in<br />
France. The range of antibiotics was negatively impacted<br />
by campaigns to limit inappropriate antibiotic<br />
prescriptions.<br />
Sales in Germany declined by 0.7 %. While our<br />
strategic brands Taxotere, Lovenox / Clexane and Lantus<br />
developed strongly, the ongoing health-policy discussions<br />
and cost containment measures, a new rebate<br />
system and new reference prices for ACE inhibitors<br />
such as Delix / Tritace impacted sales negatively.<br />
The out-licensing of the OTC business reduced sales<br />
by 2 %. In addition, signifi cant parallel imports for<br />
some strategic brands slowed down sales growth.<br />
>> 53
Change language